Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-201 in Pediatric Patients With Pearson Syndrome

Mitochondrial Diseases Clinical Trial

Official title:

A Phase I, Open Label, Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-201 in Pediatric Patients With Pearson Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06017869
• Other study ID #: MNV-010
• Status: Recruiting
• Phase: Phase 1
• Start date: July 31, 2023
• Est. completion date: December 2027

Study information

• Verified date: October 2023
• Source: Minovia Therapeutics Ltd.
• Contact: Lea Bensoussan, Msc
• Phone: + 972 586101291
• Email: lea[@]minoviatx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by mutations in genes encoded by nuclear Deoxyribonucleic Acid (DNA) or by mutations and/or deletions in the mitochondrial DNA (mtDNA). While some mitochondrial disorders only affect a single organ (e.g., the eye in Leber hereditary optic neuropathy [LHON]), many involve multiple organs. Mitochondrial disorders may present at any age and a frequent feature is the increasing number of organs involved in the course of the disease.

Minovia Therapeutics Ltd. ("Minovia") is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology (MAT). MNV-201 is a cell therapy produced by MAT that consists of the participant's autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) enriched with allogeneic placental-derived mitochondria, manufactured in Minovia's GMP facility.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: December 2027
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

1. Male or female participants aged from 1 to 18 years old.

2. Diagnosis of Pearson Syndrome

3. Body weight = 10 kg.

4. Participant has anemia and/or thrombocytopenia, and/or leukopenia and/or blood transfusion dependent (receives blood transfusions every 6 weeks or less).

5. Participant is medically able to undergo the study interventions, as determined by the investigator.

6. Participant's living parent(s) and/or legal guardian(s) able to understand and provide voluntary written informed consent.

Exclusion Criteria:

1. History of infection with HIV-1, HIV-2, and HTLV I/II.

2. Current active infection with HBV (including HBcore and HBsAg positive), HCV, HTLV I/II, Treponema Pallidum and HIV I-II

3. Participant has been diagnosed with Myelodysplastic Syndrome, by FISH and/or karyotype.

4. Participant is unable to undergo leukapheresis.

5. Total number of CD34+ cells collected is lower than 20x106 cells

6. Participant has known hypersensitivity to murine proteins or iron-dextran.

7. Participant has chronic severe infection.

8. Participant has disease or condition that may risk the participant or interfere with the ability to interpret the study results.

9. History of malignancy

10. History of treatment with gene therapy, bone marrow or allogeneic cord blood transplantation.

11. Currently participating in another clinical trial, or participation in another clinical trial within 1 year prior to study enrollment.

12. In the opinion of the Investigator, the participant is unsuitable for participating in the study for any reason.

Related Conditions & MeSH terms

• Lipid Metabolism, Inborn Errors
• Mitochondrial Diseases
• Muscular Diseases
• Pearson Syndrome
• Syndrome

Intervention

Biological:
• MNV-201
Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by leukapheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.

Locations

Country	Name	City	State
Israel	Sheba Medical Center	Ramat Gan

Sponsors (1)

Lead Sponsor	Collaborator
Minovia Therapeutics Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of treatment-related adverse events	Occurrence of treatment-related adverse events as assessed by CTCAE v5.0 following MNV-201 infusion.	12 months post treatment.
Secondary	Change in Quality of Life (QoL) questionnaire IPMDS (International Pediatric Mitochondrial Disease Scale) scores, since Baseline and during a follow up period of 3-, 6- or 12-months post treatment.	The score is expressed as the percentage of items which were feasible to perform. The lower the score, the better is the child performance. The minimum score is 0% and the maximum score is 100%.	3, 6 or 12 months post treatment.
Secondary	Assessment of frequency of hospitalizations	Change in frequency of hospitalization during the 12 months after treatment compared to the 6 months period before treatment.	12 months post treatment
Secondary	Assessment of lengths of hospitalizations	Change in lengths of hospitalization during the 12 months after treatment compared to the 6 months period before treatment.	12 months post treatment
Secondary	Change in Anemia	Change since Baseline in anemia during a follow up period of 3, 6 or 12 months post treatment measured by CBC.	3, 6 or 12 months post treatment
Secondary	Change in thrombocytopenia	Changes since baseline in thrombocytopenia during a follow up period of 3, 6 or 12 months post treatment measured by Complete Blood Count.	3, 6 or 12 months post treatment
Secondary	Changes in leukopenia during a follow up period of 12 months post treatment	Changes since baseline in leukopenia during a follow up period of 3, 6 or 12 months post treatment measured by Complete Blood Count.	3, 6 or 12 months post treatment
Secondary	Changes in frequency of blood transfusions during a follow up period of 12 months post treatment.	Change in frequency of blood transfusions during a follow up period of 3-, 6- or 12-months post treatment compared to the 6 months period before treatment.	3, 6 or 12 months post treatment